While trametinib effectively inhibits MEK signaling, reducing cell proliferation and increasing apoptosis in HNSCC cells, autophagy activation has emerged as a potential resistance mechanism that may limit its effectiveness. The gene discussed is MAP2K7; the disease is head and neck squamous cell carcinoma.